CorMedix (NASDAQ:CRMD) Issues Quarterly Earnings Results

CorMedix (NASDAQ:CRMD) released its quarterly earnings results on Thursday. The company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.35 by $0.08, Zacks reports. CorMedix had a net margin of 52.31% and a return on equity of 52.30%. The business had revenue of $127.43 million for the quarter, compared to analysts’ expectations of $104.96 million. During the same period in the prior year, the firm earned $0.30 earnings per share. CorMedix’s revenue was up 226.1% compared to the same quarter last year.

Here are the key takeaways from CorMedix’s conference call:

• CorMedix reported Q1 2026 net revenue of $127.4 million and adjusted EBITDA of $70 million, both reflecting strong execution and ahead of expectations. Management said the quarter benefited from durable DefenCath demand and the full-quarter contribution from the Melinta portfolio.
• The company raised full-year guidance, increasing net revenue to $325 million-$345 million and adjusted EBITDA to $115 million-$135 million. It also lifted DefenCath guidance to $175 million-$195 million, citing continued utilization strength.
• Management expects DefenCath revenue variability in the second half of 2026 as TDAPA reimbursement expires and the product moves to the post-TDAPA add-on phase. The company expects a higher net selling price in 2027 and said its near-term priority is to maintain or grow patient utilization.
• Preliminary top-line results from the ReSPECT phase III study showed REZZAYO met its primary endpoint and was non-inferior to standard antifungal therapy, with a favorable safety profile. CorMedix said the data support pursuing an sNDA submission in the second half of 2026 and a potential commercial launch in 2027.
• The Nutri-Guard TPN study is progressing slowly, with enrollment at only about one-third of the level needed for the interim analysis and completion now trending toward 2028. CorMedix plans to add sites and seek an FDA protocol amendment to broaden eligibility and speed enrollment.

CorMedix Trading Up 5.7%

Shares of NASDAQ CRMD opened at $7.93 on Friday. The company’s 50 day simple moving average is $7.09 and its 200 day simple moving average is $8.67. CorMedix has a fifty-two week low of $6.13 and a fifty-two week high of $17.43. The firm has a market capitalization of $622.03 million, a P/E ratio of 3.97 and a beta of 1.46. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.11 and a quick ratio of 1.94.

Key Headlines Impacting CorMedix

Here are the key news stories impacting CorMedix this week:

• Positive Sentiment: CorMedix delivered a major revenue beat in Q1, with sales up sharply year over year and earnings above expectations. CorMedix (CRMD) Q1 Earnings and Revenues Beat Estimates
• Positive Sentiment: The company raised FY 2026 revenue guidance to $325 million-$345 million, above the Street’s current expectations, which suggests momentum may continue. Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Investor enthusiasm was evident in pre-earnings trading, including unusually heavy call-option buying, signaling bullish sentiment around CRMD. Cormedix Inc (CRMD) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic …
• Neutral Sentiment: Multiple earnings-call transcript and snapshot articles mostly reiterate the same beats and guidance raise, offering little new information beyond the initial results. CorMedix (CRMD) Q1 2026 Earnings Transcript

Hedge Funds Weigh In On CorMedix

Large investors have recently bought and sold shares of the business. Comerica Bank lifted its holdings in CorMedix by 454.6% in the third quarter. Comerica Bank now owns 2,690 shares of the company’s stock valued at $31,000 after buying an additional 2,205 shares during the period. Canada Pension Plan Investment Board acquired a new stake in CorMedix in the second quarter worth $42,000. Kestra Advisory Services LLC acquired a new stake in CorMedix in the fourth quarter worth $49,000. Caitong International Asset Management Co. Ltd raised its holdings in CorMedix by 666.6% in the third quarter. Caitong International Asset Management Co. Ltd now owns 4,385 shares of the company’s stock worth $51,000 after purchasing an additional 3,813 shares during the period. Finally, Northwestern Mutual Wealth Management Co. acquired a new stake in CorMedix in the third quarter worth $55,000. 34.18% of the stock is currently owned by institutional investors and hedge funds.

CorMedix declared that its Board of Directors has authorized a stock buyback plan on Monday, February 2nd that allows the company to repurchase $75.00 million in outstanding shares. This repurchase authorization allows the company to purchase up to 12.3% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s board of directors believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several analysts have recently commented on CRMD shares. Citizens Jmp reissued a “market outperform” rating and set a $19.00 price target on shares of CorMedix in a research note on Tuesday, April 28th. D. Boral Capital reissued a “buy” rating and set a $14.00 price target on shares of CorMedix in a research note on Monday, April 27th. Needham & Company LLC increased their price objective on shares of CorMedix from $14.00 to $15.00 and gave the company a “buy” rating in a report on Monday, April 27th. Weiss Ratings restated a “hold (c)” rating on shares of CorMedix in a report on Wednesday, January 21st. Finally, HC Wainwright cut their price objective on shares of CorMedix from $18.00 to $13.00 and set a “buy” rating on the stock in a report on Friday, January 23rd. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, CorMedix presently has an average rating of “Moderate Buy” and an average price target of $15.00.

About CorMedix

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.